Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Clinical trial NCT04243122 · COMPLETED

Trial details

NCT number: NCT04243122
Sponsor: Ottawa Hospital Research Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myeloproliferative Neoplasm (MPN)Essential Thrombocythemia (ET)JAK2 Mutation Polycythemia Vera (PV)Primary Myelofibrosis Venous Thromboembolism (VTE)

Start date: 2021-02-17
Primary completion: 2023-10-31
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.